Estimation of life-years gained and cost effectiveness based on cause-specific mortality

Health Economics

Volumn 20, Issue 7, 2011, Pages 842-852

  Kim, Lois G ^a   Thompson, Simon G ^b  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Cause specific mortality; Competing risks; Cost effectiveness analysis; Life years gained

Indexed keywords

ABDOMINAL AORTA ANEURYSM; ACCURACY; ANALYTIC METHOD; ARTICLE; CAUSE SPECIFIC MORTALITY; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; HEALTH CARE COST; HEALTH ECONOMIC MODEL; INCREMENTAL COST; LIFE YEARS GAINED; MEDICAL PARAMETERS; MORTALITY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEARS GAINED; RANDOMIZED CONTROLLED TRIAL (TOPIC);

AORTIC ANEURYSM, ABDOMINAL; CAUSE OF DEATH; COST-BENEFIT ANALYSIS; HUMANS; KAPLAN-MEIER ESTIMATE; MARKOV CHAINS; MASS SCREENING; MODELS, ECONOMIC; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 79953751838     PISSN: 10579230     EISSN: 10991050     Source Type: Journal    
DOI: 10.1002/hec.1648     Document Type: Article

References (25)

1. Bang H, Tsiatis AA. 2000. Estimating medical costs with censored data. Biometrika 87(2): 329-343.
2. Briggs AH, O'Brien BJ, Blackhouse G. 2002. Thinking outside the box: recent advances in the analysis and presentation of uncertainty in cost-effectiveness studies. Annual Review of Public Health 23:377-401. (Pubitemid 34508080)
3. Carides GW, Heyse JF, Iglewicz B. 2000. A regression-based method for estimating mean treatment cost in the presence of right-censoring. Biostatistics 1(3): 299-313.
4. Clayton D, Spiegelhalter D, Dunn G, Pickles A. 1998. Analysis of longitudinal binary data from multiphase sampling. Journal of Royal Statistical Society B 60(1): 71-87. (Pubitemid 128656494)
5. Collett D. 2003. Modelling Survival Data in Medical Research (2nd edn). Chapman & Hall: London; 340.
6. Cox DR. 2005. Combination of data. In Encyclopedia of Statistical Sciences, Kotz S (ed.), Wiley: Hoboken, New Jersey; 1074-1081.
7. Dunn G. 2000. Statistics in Psychiatry. Arnold: London; 73.
8. Freidlin B, Korn EL. 2005. Testing treatment effects in the presence of competing risks. Statistics in Medicine 24(11): 1703-1712. (Pubitemid 40754089)
9. Gooley TA, Leisenring W, Crowley J, Storer BE. 1999. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Statistics in Medicine 18(6): 695-706. (Pubitemid 29126745)
10. Hardy RJ, Thompson SG. 1996. A likelihood approach to meta-analysis with random effects. Statistics in Medicine 15(6): 619-629.
11. HM Treasury. 2003. The Green Book: Appraisal and Evaluation in Central Government. Great Britain HM Treasury: London.
12. Kim LG, Scott RAP, Ashton HA, Thompson SG. 2007a. A sustained mortality benefit from screening for abdominal aortic aneurysm. Annals of Internal Medicine 146(10): 699-706. (Pubitemid 351639997)
13. Kim LG, Thompson SG, Briggs AH, Buxton MJ, Campbell HE. 2007b. How cost-effective is screening for abdominal aortic aneurysms? Journal of Medical Screening 14(1): 46-52.
14. Klein JP, Moeschberger ML. 2003. Survival Analysis: Techniques for Censored and Truncated Data (2nd edn). Springer: New York; 118.
15. Lin CC, Johnson NJ. 2006. Decomposition of life expectancy and expected life-years lost by disease. Statistics in Medicine 25: 1922-1936. (Pubitemid 43826843)
16. Lin DY, Feuer EJ, Etzioni R, Wax Y. 1997. Estimating medical costs from incomplete follow-up data. Biometrics 53(2): 419-434. (Pubitemid 27262208)
17. Multi-centre Aneurysm Screening Study Group. 2002. The Multi-centre Aneurysm Screening Study (MASS) into the effect of abdominal aortic aneurysm screening on mortality in men: a randomised controlled trial. Lancet 360: 1531-1539.
18. MRC Biostatistics Unit. 2007. STATA software for cause-specific cost-effectiveness analysis. Available from: www.mrc-bsu.cam.ac.uk/BSUsite/ Software/Stata.shtml.
19. Office of National Statistics. 2000. Mortality Statistics Series DH2 no.27. Deaths in England and Wales.
20. StataCorp. STATA 9.2. StataCorp: College Station, TX; 2006.
21. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. 1996. Recommendations of the panel on cost-effectiveness in health and medicine. Journal of American Medical Association 276(15): 1253-1258. (Pubitemid 26337709)
22. Willan AR, Lin DY. 2001. Incremental net benefit in randomized clinical trials. Statistics in Medicine 20(11): 1563-1574. (Pubitemid 32577128)
23. Willan AR, Lin DY, Manca A. 2005. Regression methods for cost-effectiveness analysis with censored data. Statistics in Medicine 24(1): 131-145. (Pubitemid 40074070)
24. Young TA. 2005. Estimating mean total costs in the presence of censoring: a comparative assessment of methods. Pharmacoeconomics 23(12): 1229-1242. (Pubitemid 41803319)
25. Zhao H, Tian L. 2001. On estimating medical cost and incremental cost-effectiveness ratios with censored data. Biometrics 57(4): 1002-1008. (Pubitemid 33108090)